{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:44:11Z","timestamp":1793105051067,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"40","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.vaccine.2022.08.048","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T05:32:28Z","timestamp":1661923948000},"page":"5781-5790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-na\u00efve adults"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6614-3560","authenticated-orcid":false,"given":"Jack N","family":"Hutter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Robben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Hamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dallas R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Bolton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelina","family":"Angov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Lanar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mangala","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary R.","family":"Matyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Bergmann-Leitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine A.","family":"Soisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman C.","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viseth","family":"Ngauy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Regules","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheetij","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.vaccine.2022.08.048_b0005","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa2026330","article-title":"Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention","volume":"385","author":"Chandramohan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.08.048_b0010","unstructured":"RTs, doctors team up to lead successful asthma program. Healthc Demand Dis Manag. 1999;5:81-5."},{"key":"10.1016\/j.vaccine.2022.08.048_b0015","doi-asserted-by":"crossref","unstructured":"Zavala F, Cochrane AH, Nardin EH, Nussenzweig RS, Nussenzweig V. Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes. J Exp Med. 1983;157:1947-57.","DOI":"10.1084\/jem.157.6.1947"},{"issue":"5","key":"10.1016\/j.vaccine.2022.08.048_b0020","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1586\/erv.11.57","article-title":"The RTS, S vaccine candidate for malaria","volume":"10","author":"Regules","year":"2011","journal-title":"Expert rev vaccines"},{"issue":"10287","key":"10.1016\/j.vaccine.2022.08.048_b0025","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","article-title":"Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial","volume":"397","author":"Datoo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.08.048_b0030","doi-asserted-by":"crossref","first-page":"46621","DOI":"10.1038\/srep46621","article-title":"Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine","volume":"7","author":"Collins","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2022.08.048_b0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1084\/jem.20040989","article-title":"The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion","volume":"201","author":"Coppi","year":"2005","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.048_b0040","article-title":"Comparative population structure of Plasmodium falciparum circumsporozoite protein NANP repeat lengths in Lilongwe","volume":"3","author":"Bowman","year":"2013","journal-title":"Malawi Sci Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.048_b0045","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0166-6851(87)90073-9","article-title":"Strain variation in the circumsporozoite protein gene of Plasmodium falciparum","volume":"22","author":"Lockyer","year":"1987","journal-title":"Mol Biochem Parasitol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.048_b0050","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1084\/jem.156.1.20","article-title":"Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax","volume":"156","author":"Nardin","year":"1982","journal-title":"J Exp Med"},{"issue":"20","key":"10.1016\/j.vaccine.2022.08.048_b0055","doi-asserted-by":"crossref","first-page":"7817","DOI":"10.1073\/pnas.1205737109","article-title":"Unexpected fold in the circumsporozoite protein target of malaria vaccines","volume":"109","author":"Doud","year":"2012","journal-title":"PNAS"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.048_b0060","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-017-0027-3","article-title":"Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFN\u03b3 response promoting vaccine immunogenicity","volume":"2","author":"Coccia","year":"2017","journal-title":"npj Vaccines"},{"issue":"26","key":"10.1016\/j.vaccine.2022.08.048_b0065","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1515257","article-title":"Seven-Year Efficacy of RTS, S\/AS01 Malaria Vaccine among Young African Children","volume":"374","author":"Olotu","year":"2016","journal-title":"N Engl J Med"},{"issue":"43","key":"10.1016\/j.vaccine.2022.08.048_b0070","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1016\/j.vaccine.2021.09.024","article-title":"A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS, S\/AS01(E) in a controlled human malaria infection challenge","volume":"39","author":"Moon","year":"2021","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2022.08.048_b0075","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/infdis\/jiw237","article-title":"Fractional Third and Fourth Dose of RTS, S\/AS01 Malaria Candidate Vaccine: a Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study","volume":"214","author":"Regules","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.08.048_b0080","doi-asserted-by":"crossref","first-page":"260","DOI":"10.12688\/wellcomeopenres.16224.1","article-title":"Cost-effectiveness and public health impact of RTS, S\/AS01 (E) malaria vaccine in Malawi, using a Markov static model","volume":"5","author":"Ndeketa","year":"2020","journal-title":"Wellcome open res"},{"issue":"21","key":"10.1016\/j.vaccine.2022.08.048_b0085","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMoa1505819","article-title":"Genetic diversity and protective efficacy of the RTS, S\/AS01 Malaria vaccine","volume":"373","author":"Neafsey","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2022.08.048_b0090","doi-asserted-by":"crossref","first-page":"e111020","DOI":"10.1371\/journal.pone.0111020","article-title":"IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice","volume":"9","author":"Schwenk","year":"2014","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.vaccine.2022.08.048_b0095","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/infdis\/171.6.1576","article-title":"Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine","volume":"171","author":"Gordon","year":"1995","journal-title":"J Infect Dis"},{"issue":"31","key":"10.1016\/j.vaccine.2022.08.048_b0100","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1016\/j.vaccine.2017.05.070","article-title":"Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013","volume":"35","author":"Genito","year":"2017","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2022.08.048_b0105","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/14760584.2020.1745636","article-title":"Army Liposome Formulation (ALF) family of vaccine adjuvants","volume":"19","author":"Alving","year":"2020","journal-title":"Expert rev vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2022.08.048_b0110","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.bbamem.2014.12.005","article-title":"Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate","volume":"1848","author":"Beck","year":"2015","journal-title":"Biochim Biophys Acta"},{"issue":"42","key":"10.1016\/j.vaccine.2022.08.048_b0115","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1016\/j.vaccine.2015.09.001","article-title":"Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21","volume":"33","author":"Beck","year":"2015","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.08.048_b0120","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1517\/17425247.2016.1151871","article-title":"Liposomal adjuvants for human vaccines","volume":"13","author":"Alving","year":"2016","journal-title":"Expert opinion on drug delivery"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.048_b0125","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35452-x","article-title":"Identification of Immune Signatures of Novel Adjuvant Formulations Using Machine Learning","volume":"8","author":"Chaudhury","year":"2018","journal-title":"Sci Rep"},{"issue":"29","key":"10.1016\/j.vaccine.2022.08.048_b0130","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1016\/j.vaccine.2019.05.059","article-title":"Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ)","volume":"37","author":"Cawlfield","year":"2019","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.048_b0135","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-019-3014-5","article-title":"Comparison of immunogenicity and safety outcomes of a malaria vaccine FMP013\/ALFQ in rhesus macaques (Macaca mulatta) of Indian and Chinese origin","volume":"18","author":"Martin","year":"2019","journal-title":"Malar J"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.048_b0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-08526-5","article-title":"Delayed fractional dose regimen of the RTS, S\/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum opsonophagocytosis","volume":"7","author":"Chaudhury","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2022.08.048_b0145","doi-asserted-by":"crossref","unstructured":"Moon JE, Ockenhouse C, Regules JA, Vekemans J, Lee C, Chuang I, et al. A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S\/AS01E and RTS,S\/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults. J Infect Dis. 2020;222:1681-91.","DOI":"10.1093\/infdis\/jiaa421"},{"key":"10.1016\/j.vaccine.2022.08.048_b0150","doi-asserted-by":"crossref","unstructured":"Zou X, House BL, Zyzak MD, Richie TL, Gerbasi VR. Towards an optimized inhibition of liver stage development assay (ILSDA) for Plasmodium falciparum. Malar J. 2013;12:394.","DOI":"10.1186\/1475-2875-12-394"},{"key":"10.1016\/j.vaccine.2022.08.048_b0155","doi-asserted-by":"crossref","first-page":"101345","DOI":"10.1016\/j.mex.2021.101345","article-title":"Multiplex serological assay for establishing serological profiles of polymorphic, closely related peptide antigens","volume":"8","author":"Bolton","year":"2021","journal-title":"MethodsX"},{"issue":"6","key":"10.1016\/j.vaccine.2022.08.048_b0160","first-page":"968","article-title":"Breadth of humoral immune responses to the C-terminus of the circumsporozoite protein is associated with protective efficacy induced by the RTS","volume":"39","author":"Chaudhury","year":"2021","journal-title":"S malaria vaccine Vaccine"},{"key":"10.1016\/j.vaccine.2022.08.048_b0165","doi-asserted-by":"crossref","unstructured":"Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, et al. DNA prime\/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One. 2013;8:e55571.","DOI":"10.1371\/journal.pone.0055571"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.048_b0170","doi-asserted-by":"crossref","DOI":"10.1038\/srep27944","article-title":"Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine","volume":"6","author":"Farooq","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.048_b0175","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-018-1186-4","article-title":"Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS, S\/AS01E vaccination in African children","volume":"16","author":"Ubillos","year":"2018","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.048_b0180","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-016-1348-9","article-title":"The biological function of antibodies induced by the RTS, S\/AS01 malaria vaccine candidate is determined by their fine specificity","volume":"15","author":"Chaudhury","year":"2016","journal-title":"Malar J"},{"issue":"3","key":"10.1016\/j.vaccine.2022.08.048_b0185","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1086\/600120","article-title":"Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S\/AS01B and RTS, S\/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection","volume":"200","author":"Kester","year":"2009","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2022.08.048_b0190","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.vaccine.2020.12.023","article-title":"Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing","volume":"39","author":"Friedman-Klabanoff","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.08.048_b0195","doi-asserted-by":"crossref","unstructured":"Khan F, Porter M, Schwenk R, DeBot M, Saudan P, Dutta S. Head-to-Head Comparison of Soluble vs. Qbeta VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses. PloS one. 2015;10:e0142035.","DOI":"10.1371\/journal.pone.0142035"},{"issue":"8545","key":"10.1016\/j.vaccine.2022.08.048_b0200","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(87)90540-X","article-title":"Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine","volume":"329","author":"Ripley Ballou","year":"1987","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.vaccine.2022.08.048_b0205","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.4161\/hv.29375","article-title":"Evaluation of the immune response to RTS, S\/AS01 and RTS, S\/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-na\u00efve adults","volume":"10","author":"Leroux-Roels","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.vaccine.2022.08.048_b0210","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJM199701093360202","article-title":"A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS, S Malaria Vaccine Evaluation Group","volume":"336","author":"Stoute","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.08.048_b0215","doi-asserted-by":"crossref","unstructured":"De Becker G, Moulin V, Pajak B, Bruck C, Francotte M, Thiriart C, et al. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int Immunol. 2000;12:807-15.","DOI":"10.1093\/intimm\/12.6.807"},{"key":"10.1016\/j.vaccine.2022.08.048_b0220","doi-asserted-by":"crossref","unstructured":"Wang P. Natural and Synthetic Saponins as Vaccine Adjuvants. Vaccines (Basel). 2021;9.","DOI":"10.3390\/vaccines9030222"},{"issue":"22","key":"10.1016\/j.vaccine.2022.08.048_b0225","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.08.048_b0230","doi-asserted-by":"crossref","unstructured":"Sauboin C, Van Bellinghen LA, Van De Velde N, Van Vlaenderen I. Economic Impact of Introducing the RTS,S Malaria Vaccine: Cost-Effectiveness and Budget Impact Analysis in 41 Countries. MDM Policy Pract. 2019;4:2381468319873324.","DOI":"10.1177\/2381468319873324"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.048_b0235","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-017-1766-3","article-title":"Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes","volume":"16","author":"Phares","year":"2017","journal-title":"Malar J"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22010398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22010398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:15:59Z","timestamp":1759403759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22010398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":47,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0264410X22010398"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.08.048","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-na\u00efve adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.08.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}